Oral Factor IX concentrate from transgenic pig milk for
This technology uses genetically engineered farm animals—primarily pigs—whose mammary glands produce human blood-clotting protein Factor IX directly in their milk. The transgenic animals are engineered without a previously required 'gene rescue' technique, simplifying the production process while still achieving therapeutically useful protein levels. The Factor IX collected from the milk is processed into a concentrate that can be delivered orally, rather than by injection, to patients with Hemophilia B. Oral delivery also opens the door to tolerance induction, potentially training patients' immune systems to accept the clotting factor over time.
What you could build
A pharmaceutical-grade oral Factor IX concentrate derived from transgenic pig milk, sold to hemophilia treatment centers or specialty pharma companies as either a replacement therapy or an oral tolerization program for Hemophilia B patients.
Who in Virginia should care
Virginia-based biotech or agricultural biotech firms, or contract biologics manufacturers with large-animal transgenic capabilities, could license this for downstream drug development or partnerships with hemophilia specialty pharma.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Julian D. COOPER, William Hugold Velander, Tanya K. O'Sickey
- Granted
- February 15, 2011
- Status
- Granted patent
- Patent number
- 7888321
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.